Finding the needle in the haystack: ChromoTek develops new generation of nanobody-based research reagents
ChromoTek is a pioneer as well as a global market and product leader in the development and commercialization of reliable, high-quality research reagents.
Based in Martinsried near Munich in Germany, ChromoTek is a pioneer in the usage of nanobody-based reagents to assist the research of their customers, for example in the pharmaceutical industry. ChromoTek’s newest generation of nanobodies is ten times smaller than conventional secondary antibodies, which grants them several advantages, for example better tissue penetration, and enables them to detect individual cancer cells in organ tissues. This makes them ideal probes for a range of research approaches, for example flow cytometry, immunofluorescence and super-resolution microscopy. And recently, the small size of a ChromoTek nanobody technology was pivotal for winning the 2020 CiteAb Award “Image of the Year”.
For more information see: chromotek.com.